APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunodeficiency Virus Type-1

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Immunodeficiency Virus Type-1 Market Analysis and Forecast 2026-2032

27 December 2025191 pages

Choose your research edition.

Industry ResearchHuman Immunodeficiency Virus Type-1 Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunodeficiency Virus Type-1 Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Human Immunodeficiency Virus Type-1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunodeficiency Virus Type-1 Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunodeficiency Virus Type-1 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Human Immunodeficiency Virus Type-1 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human Immunodeficiency Virus Type-1 include AstraZeneca, Bayer, Bristol Myers Squibb, Merck & Co. Inc., Novartis, Pfizer, Viatris, GSK and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Immunodeficiency Virus Type-1, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Immunodeficiency Virus Type-1, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Immunodeficiency Virus Type-1, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Immunodeficiency Virus Type-1 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Immunodeficiency Virus Type-1 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Immunodeficiency Virus Type-1 revenue, projected growth trends, production technology, application and end-user industry.

Human Immunodeficiency Virus Type-1 Segment by Company

AstraZeneca

Bayer

Bristol Myers Squibb

Merck & Co. Inc.

Novartis

Pfizer

Viatris

GSK

Roche

Sanofi

Human Immunodeficiency Virus Type-1 Segment by Type

Integrase Inhibitor

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Protease Inhibitors (PIs)

Others

Human Immunodeficiency Virus Type-1 Segment by Application

Retail Pharmacies

Hospital Pharmacies

Human Immunodeficiency Virus Type-1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus Type-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus Type-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus Type-1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Immunodeficiency Virus Type-1 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Immunodeficiency Virus Type-1 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Immunodeficiency Virus Type-1 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Integrase Inhibitor Major Player Table 3. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Major Player Table 4. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Major Player Table 5. Protease Inhibitors (PIs) Major Player Table 6. Others Major Player Table 7. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacies Major Player Table 9. Hospital Pharmacies Major Player Table 10. Human Immunodeficiency Virus Type-1 Industry Trends Table 11. Human Immunodeficiency Virus Type-1 Industry Drivers Table 12. Human Immunodeficiency Virus Type-1 Industry Opportunities and Challenges Table 13. Human Immunodeficiency Virus Type-1 Industry Restraints Table 14. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Human Immunodeficiency Virus Type-1 Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Human Immunodeficiency Virus Type-1 Market Share by Region (2021-2026) Table 17. Global Human Immunodeficiency Virus Type-1 Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Human Immunodeficiency Virus Type-1 Market Share by Region (2027-2032) Table 19. Global Human Immunodeficiency Virus Type-1 Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Players (2021-2026) Table 21. Global Human Immunodeficiency Virus Type-1 Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Human Immunodeficiency Virus Type-1 Key Players Headquarters & Area Served Table 23. Global Human Immunodeficiency Virus Type-1 Players, Product Type & Application Table 24. Global Human Immunodeficiency Virus Type-1 Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Human Immunodeficiency Virus Type-1 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Human Immunodeficiency Virus Type-1 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2021-2026) Table 31. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2027-2032) Table 32. Global Human Immunodeficiency Virus Type-1 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2021-2026) Table 36. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2027-2032) Table 37. AstraZeneca Company Information Table 38. AstraZeneca Business Overview Table 39. AstraZeneca Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. AstraZeneca Human Immunodeficiency Virus Type-1 Product Portfolio Table 41. AstraZeneca Recent Development Table 42. Bayer Company Information Table 43. Bayer Business Overview Table 44. Bayer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Bayer Human Immunodeficiency Virus Type-1 Product Portfolio Table 46. Bayer Recent Development Table 47. Bristol Myers Squibb Company Information Table 48. Bristol Myers Squibb Business Overview Table 49. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Portfolio Table 51. Bristol Myers Squibb Recent Development Table 52. Merck & Co. Inc. Company Information Table 53. Merck & Co. Inc. Business Overview Table 54. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Portfolio Table 56. Merck & Co. Inc. Recent Development Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Novartis Human Immunodeficiency Virus Type-1 Product Portfolio Table 61. Novartis Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Pfizer Human Immunodeficiency Virus Type-1 Product Portfolio Table 66. Pfizer Recent Development Table 67. Viatris Company Information Table 68. Viatris Business Overview Table 69. Viatris Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Viatris Human Immunodeficiency Virus Type-1 Product Portfolio Table 71. Viatris Recent Development Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. GSK Human Immunodeficiency Virus Type-1 Product Portfolio Table 76. GSK Recent Development Table 77. Roche Company Information Table 78. Roche Business Overview Table 79. Roche Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Roche Human Immunodeficiency Virus Type-1 Product Portfolio Table 81. Roche Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Sanofi Human Immunodeficiency Virus Type-1 Product Portfolio Table 86. Sanofi Recent Development Table 87. North America Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Human Immunodeficiency Virus Type-1 Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Human Immunodeficiency Virus Type-1 Revenue by Country (US$ Million) & (2027-2032) Table 101. China Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 102. China Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 103. China Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 104. China Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Human Immunodeficiency Virus Type-1 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Human Immunodeficiency Virus Type-1 Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Human Immunodeficiency Virus Type-1 Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Human Immunodeficiency Virus Type-1 Image Figure 2. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunodeficiency Virus Type-1 Market Size Share 2021 VS 2025 VS 2032 Figure 4. Integrase Inhibitor Image Figure 5. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Image Figure 6. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Image Figure 7. Protease Inhibitors (PIs) Image Figure 8. Others Image Figure 9. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Human Immunodeficiency Virus Type-1 Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacies Image Figure 12. Hospital Pharmacies Image Figure 13. Global Human Immunodeficiency Virus Type-1 Market Size (US$ Million) & (2021-2032) Figure 14. Global Human Immunodeficiency Virus Type-1 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human Immunodeficiency Virus Type-1 Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Human Immunodeficiency Virus Type-1 Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Immunodeficiency Virus Type-1 Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2021-2032) Figure 21. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2021-2032) Figure 24. North America Human Immunodeficiency Virus Type-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032) Figure 26. North America Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032) Figure 27. North America Human Immunodeficiency Virus Type-1 Revenue Share by Country (2021-2032) Figure 28. United States Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Human Immunodeficiency Virus Type-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032) Figure 33. Europe Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032) Figure 34. Europe Human Immunodeficiency Virus Type-1 Revenue Share by Country (2021-2032) Figure 35. Germany Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Human Immunodeficiency Virus Type-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032) Figure 45. China Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032) Figure 46. Asia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032) Figure 48. Asia Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032) Figure 49. Asia Human Immunodeficiency Virus Type-1 Revenue Share by Region (2021-2032) Figure 50. Japan Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Human Immunodeficiency Virus Type-1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032) Figure 58. SAMEA Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032) Figure 59. SAMEA Human Immunodeficiency Virus Type-1 Revenue Share by Country (2021-2032) Figure 60. Brazil Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Human Immunodeficiency Virus Type-1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Integrase Inhibitor
  • Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (PIs)
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
Companies covered
  • AstraZeneca
  • Bayer
  • Bristol Myers Squibb
  • Merck & Co. Inc.
  • Novartis
  • Pfizer
  • Viatris
  • GSK
  • Roche
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Immunodeficiency Virus Type-1 Market by Type
  3. 1.2.1 Global Human Immunodeficiency Virus Type-1 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Integrase Inhibitor
  5. 1.2.3 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
  6. 1.2.4 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  7. 1.2.5 Protease Inhibitors (PIs)
  8. 1.2.6 Others
  9. 1.3 Human Immunodeficiency Virus Type-1 Market by Application
  10. 1.3.1 Global Human Immunodeficiency Virus Type-1 Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacies
  12. 1.3.3 Hospital Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Human Immunodeficiency Virus Type-1 Market Dynamics
  1. 2.1 Human Immunodeficiency Virus Type-1 Industry Trends
  2. 2.2 Human Immunodeficiency Virus Type-1 Industry Drivers
  3. 2.3 Human Immunodeficiency Virus Type-1 Industry Opportunities and Challenges
  4. 2.4 Human Immunodeficiency Virus Type-1 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Immunodeficiency Virus Type-1 Market Perspective (2021-2032)
  2. 3.2 Global Human Immunodeficiency Virus Type-1 Growth Trends by Region
  3. 3.2.1 Global Human Immunodeficiency Virus Type-1 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Immunodeficiency Virus Type-1 Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Immunodeficiency Virus Type-1 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Immunodeficiency Virus Type-1 Revenue by Players
  2. 4.1.1 Global Human Immunodeficiency Virus Type-1 Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Immunodeficiency Virus Type-1 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Immunodeficiency Virus Type-1 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Immunodeficiency Virus Type-1 Key Players Headquarters & Area Served
  7. 4.4 Global Human Immunodeficiency Virus Type-1 Players, Product Type & Application
  8. 4.5 Global Human Immunodeficiency Virus Type-1 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Immunodeficiency Virus Type-1 Market CR5 and HHI
  11. 4.6.3 2025 Human Immunodeficiency Virus Type-1 Tier 1, Tier 2, and Tier 3
5 Human Immunodeficiency Virus Type-1 Market Size by Type
  1. 5.1 Global Human Immunodeficiency Virus Type-1 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 5.3 Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2021-2032)
6 Human Immunodeficiency Virus Type-1 Market Size by Application
  1. 6.1 Global Human Immunodeficiency Virus Type-1 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  3. 6.3 Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca Human Immunodeficiency Virus Type-1 Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Human Immunodeficiency Virus Type-1 Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Bristol Myers Squibb
  14. 7.3.1 Bristol Myers Squibb Company Information
  15. 7.3.2 Bristol Myers Squibb Business Overview
  16. 7.3.3 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Portfolio
  18. 7.3.5 Bristol Myers Squibb Recent Developments
  19. 7.4 Merck & Co. Inc.
  20. 7.4.1 Merck & Co. Inc. Company Information
  21. 7.4.2 Merck & Co. Inc. Business Overview
  22. 7.4.3 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Portfolio
  24. 7.4.5 Merck & Co. Inc. Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Human Immunodeficiency Virus Type-1 Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Human Immunodeficiency Virus Type-1 Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Viatris
  38. 7.7.1 Viatris Company Information
  39. 7.7.2 Viatris Business Overview
  40. 7.7.3 Viatris Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Viatris Human Immunodeficiency Virus Type-1 Product Portfolio
  42. 7.7.5 Viatris Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GSK Human Immunodeficiency Virus Type-1 Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 Roche
  50. 7.9.1 Roche Company Information
  51. 7.9.2 Roche Business Overview
  52. 7.9.3 Roche Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Roche Human Immunodeficiency Virus Type-1 Product Portfolio
  54. 7.9.5 Roche Recent Developments
  55. 7.10 Sanofi
  56. 7.10.1 Sanofi Company Information
  57. 7.10.2 Sanofi Business Overview
  58. 7.10.3 Sanofi Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sanofi Human Immunodeficiency Virus Type-1 Product Portfolio
  60. 7.10.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Human Immunodeficiency Virus Type-1 Revenue (2021-2032)
  2. 8.2 North America Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032)
  5. 8.3 North America Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032)
  9. 8.5 North America Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Immunodeficiency Virus Type-1 Revenue by Country
  11. 8.6.1 North America Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Immunodeficiency Virus Type-1 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Human Immunodeficiency Virus Type-1 Revenue (2021-2032)
  2. 9.2 Europe Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032)
  5. 9.3 Europe Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032)
  9. 9.5 Europe Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Immunodeficiency Virus Type-1 Revenue by Country
  11. 9.6.1 Europe Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Immunodeficiency Virus Type-1 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Human Immunodeficiency Virus Type-1 Revenue (2021-2032)
  2. 10.2 China Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 10.2.1 China Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026)
  4. 10.2.2 China Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032)
  5. 10.3 China Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032)
  6. 10.4 China Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  7. 10.4.1 China Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026)
  8. 10.4.2 China Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032)
  9. 10.5 China Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Immunodeficiency Virus Type-1 Revenue (2021-2032)
  2. 11.2 Asia Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032)
  5. 11.3 Asia Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032)
  9. 11.5 Asia Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Immunodeficiency Virus Type-1 Revenue by Country
  11. 11.6.1 Asia Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Immunodeficiency Virus Type-1 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Immunodeficiency Virus Type-1 Revenue (2021-2032)
  2. 12.2 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Immunodeficiency Virus Type-1 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Immunodeficiency Virus Type-1 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country
  11. 12.6.1 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Immunodeficiency Virus Type-1 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst